INGREDIENTS : N-Acetyl L-Carnitine HCl, Vegetable capsule (Hydroxypropyl methylcellulose), Succinic acid

Patients undergoing tirzepatide therapy commonly experience: Improved blood pressure: reductions in systolic and diastolic blood pressure have been observed across tirzepatide clinical trials Better cholesterol profiles: reductions in LDL and triglycerides, with improvements in HDL Improved blood glucose regulation: tirzepatide significantly improves insulin sensitivity and reduces fasting glucose, even in patients without diabetes Reduction in waist circumference: visceral fat reduction, which is directly associated with reduced cardiovascular and metabolic risk Preservation of lean muscle mass: unlike traditional caloric restriction, which often results in 2530% of weight loss coming from muscle, tirzepatide promotes preferential fat loss Potential hormonal benefits: emerging evidence suggests that fat mass reduction lowers aromatase activity, which may support healthier testosterone-to-estrogen balance For patients managing multiple metabolic conditions simultaneously, GLP-1/GIP weight loss therapy represents an opportunity to address root causes, rather than individual symptoms, through a single medically supervised intervention

Examples include the impact of behavioral/lifestyle modification on study outcomes
In contrast there are some downregulated biomarkers upon anti-pollution treatment: Vitamin E content, cholesterol content, skin lipid level (triglycerides, wax esters, free fatty acids
In contrast, powders and spices can contain as little as 2% of curcuminoids